Molecular Imaging

In a recent interview, Vivianne Freitas, M.D., discussed new research findings on positron emission mammography (PEM), pertinent benefits of the technology and its potential as a viable alternative in the future to conventional imaging techniques for breast cancer screening.

Catch up on the top radiology content of the past week.

Findings from a new pilot study showed that low-dose positron emission mammography (PEM) detected 96 percent of malignant index lesions and had a 46 percent lower false-positive rate in comparison to breast MRI.

For the detection of nodal metastases in patients with early-stage cervical cancer, 18F FDG PET-CT offered a sensitivity rate that was double that of CT and 32 percent higher than MRI, according to newly published research.

Catch up on the most-well viewed radiology content in January 2024.

Catch up on the top radiology content of the past week.

Patients with localized high-risk prostate cancer and midline radiotracer activity in the prostate had over double the incidence of urethral hyperintensity on T2W MRI, according to research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).

For patients with recurrent prostate cancer, PET scanning with 18F-flotufolastat led to major changes in treatment for 80 percent of patients and 75 percent of patients with a changed treatment focus to watchful waiting had negative scans, according to new research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).

The syngo Virtual Cockpit platform reportedly enables remote access and image acquisition for CT, MRI and positron emission tomography (PET), and facilitates clinician collaboration across multiple sites.

Catch up on the top radiology content of the past week.

In addition to detecting more than double the number of distant lymph nodes and distant lesions in comparison to conventional imaging with computed tomography (CT), PSMA PET/CT reportedly changed management for 32 percent of patients.

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

In a recent proof-of-concept trial assessing the combination of aducanumab infusion with MRI-guided focused ultrasound to open the blood-brain barrier, researchers found significant reductions in amyloid-beta load at 26 weeks in patients with Alzheimer’s disease.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Dr. Kottler sat down with Diagnostic Imaging at RSNA 2023 to discuss AI imaging milestones and the potential impact of AI on workflows in radiology.

Catch up on the top radiology content of the past week.

The Biograph Vision.X positron emission tomography/computed tomography (PET/CT) reportedly offers an industry-leading time of flight (TOF) and detector technology that facilitates the diagnosis of smaller lesions.

Catch up on the top radiology content of the past week.

For patients who had a complete metabolic response to radiation treatment for head and neck cancer, the authors of a recent study found that surveillance imaging with PET/CT, MRI or CT did not improve outcomes in comparison to expectant management.

Radiology experts discuss the current knowledge and use of PSMA-PET screening among colleagues, as well as unmet needs.

Imaging experts compare gallium-based agents to non–gallium-based agents for prostate cancer screening.

Experts highlight gallium-based and PyL PSMA-PET scans for use in prostate cancer, commenting on approvals as well as how the agents are made.

Two experts review SNMMI (Society of Nuclear Medicine and Molecular Imaging) guidelines for use of PSMA PET scans in prostate cancer detection, as well as awareness about this new modality within the patient community.

Experts highlight the use of PSMA PET scans as a recent and accurate imaging method for prostate cancer screening.

In a recent video interview series, Dushyant Sahani, M.D., discussed the critical role of contrast media in diagnostic imaging, lessons learned from the contrast media shortage, key considerations with generic agents and currently unmet needs with contrast agents.

Imaging experts discuss the challenges with traditional imaging modalities for prostate cancer, commenting on the bone scan and CT scan.

Experts review traditional imaging modalities for prostate cancer, highlighting the most commonly used modalities.

Catch up on the top radiology content of the past week.

Various organizations have applauded the decision by the CMS to remove National Coverage Determination (NCD) limitations to coverage for amyloid PET scans, including the limitation of Medicare or Medicaid coverage to one PET scan per a patient’s lifetime. It remains to be seen, however, how coverage decisions will be made by local Medicare Administrative Contractors (MACs).